# ELTP catalysts: ELITE PHARMACEUTICALS INC /NV/ PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/eltp/catalysts

> ELITE PHARMACEUTICALS INC /NV/ (ELTP) has no upcoming catalysts in this calendar. The latest recorded is the ELITE PHARMACEUTICALS INC /NV/ earnings report, November 12, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | ELITE PHARMACEUTICALS INC /NV/ |
| Ticker | ELTP (OTC) |
| SEC CIK | 1053369 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/eltp |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 29, 2022 | [ELITE PHARMACEUTICALS INC /NV/ FDA approval](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed, approved | "June 29, 2022 the Company received approval from the FDA for Vigabatrin Powder." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1053369/000164117225017134/form10-k.htm)) |
| November 14, 2024 | [ELITE PHARMACEUTICALS INC /NV/ earnings report](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed | "Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000149315224046001/ex99-1.htm)) |
| November 18, 2024 | [ELITE PHARMACEUTICALS INC /NV/ FDA approval](https://sec-api.dev/companies/eltp/catalysts) | ELTP | Attention | completed, approved | "November 18, 2024, the Company received approval from the FDA for Lisdex Capsules, a product indicated for the treatment of Attention" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/form10-k.htm)) |
| February 13, 2025 | [ELITE PHARMACEUTICALS INC /NV/ earnings report](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed | "Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000149315225006471/ex99-1.htm)) |
| June 30, 2025 | [ELITE PHARMACEUTICALS INC /NV/ earnings report](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed | "Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2025 and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000164117225017151/ex99-1.htm)) |
| August 14, 2025 | [ELITE PHARMACEUTICALS INC /NV/ earnings report](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed | "Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000164117225024088/ex99-1.htm)) |
| November 12, 2025 | [ELITE PHARMACEUTICALS INC /NV/ FDA approval](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed, approved | "Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000149315225021717/ex99-1.htm)) |
| November 14, 2025 | [ELITE PHARMACEUTICALS INC /NV/ earnings report](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed | "Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000149315225023629/ex99-1.htm)) |
| February 17, 2026 | [ELITE PHARMACEUTICALS INC /NV/ earnings report](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed | "Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000149315226007190/ex99-1.htm)) |
| June 29, 2026 | [ELITE PHARMACEUTICALS INC /NV/ earnings report](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed | "Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000149315226031103/ex99-1.htm)) |
| August 13, 2026 | [ELITE PHARMACEUTICALS INC /NV/ earnings report](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed | "Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 ended June 30, 2026 and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000149315226037787/ex99-1.htm)) |
| November 12, 2026 | [ELITE PHARMACEUTICALS INC /NV/ earnings report](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed | "Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2027 ended September 30, 2026 and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000149315226051484/ex99-1.htm)) |

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/eltp/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ELTP catalysts: ELITE PHARMACEUTICALS INC /NV/ PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/eltp/catalysts

```bibtex
@misc{secapidev_companies_eltp_catalysts_20261116,
  title        = {ELTP catalysts: ELITE PHARMACEUTICALS INC /NV/ PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/eltp/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_eltp_catalysts_20261116","title":"ELTP catalysts: ELITE PHARMACEUTICALS INC /NV/ PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/eltp/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
